Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Broad Device Portfolio Eclipses Lackluster Stent Sale Growth

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's medical device and diagnostics revenue grew 11.8% in the second quarter to $4.06 bil., despite a negligible increase in U.S. Cypher drug-eluting stent revenue from the year-ago period
Advertisement

Related Content

J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Advertisement
UsernamePublicRestriction

Register

MT020585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel